Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 2;10(5):520.
doi: 10.3390/antibiotics10050520.

Potential Application of Combined Therapy with Lectins as a Therapeutic Strategy for the Treatment of Bacterial Infections

Affiliations
Review

Potential Application of Combined Therapy with Lectins as a Therapeutic Strategy for the Treatment of Bacterial Infections

João Victor de Oliveira Santos et al. Antibiotics (Basel). .

Abstract

Antibiotic monotherapy may become obsolete mainly due to the continuous emergence of resistance to available antimicrobials, which represents a major uncertainty to human health. Taking into account that natural products have been an inexhaustible source of new compounds with clinical application, lectins are certainly one of the most versatile groups of proteins used in biological processes, emerging as a promising alternative for therapy. The ability of lectins to recognize carbohydrates present on the cell surface allowed for the discovery of a wide range of activities. Currently the number of antimicrobials in research and development does not match the rate at which resistance mechanisms emerge to an effective antibiotic monotherapy. A promising therapeutic alternative is the combined therapy of antibiotics with lectins to enhance its spectrum of action, minimize adverse effects, and reduce resistance to treatments. Thus, this review provides an update on the experimental application of antibiotic therapies based on the synergic combination with lectins to treat infections specifically caused by multidrug-resistant and biofilm-producing Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. We also briefly discuss current strategies involving the modulation of the gut microbiota, its implications for antimicrobial resistance, and highlight the potential of lectins to modulate the host immune response against oxidative stress.

Keywords: bacteria; biofilm; proteins; synergism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Yang S., Wu J., Ding C., Cui Y., Zhou Y., Li Y., Deng M., Wang C., Xu K., Ren J., et al. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: An observational trend study. Lancet Infect. Dis. 2017;17:716–725. doi: 10.1016/S1473-3099(17)30227-X. - DOI - PMC - PubMed
    1. Tse B.N., Adalja A.A., Houchens C., Larsen J., Inglesby T.V., Hatchett R. Challenges and opportunities of nontraditional approaches to treating bacterial infections. Clin. Infect. Dis. 2017;65:495–500. doi: 10.1093/cid/cix320. - DOI - PMC - PubMed
    1. Walvekar P., Gannimani R., Govender T. Combination drug therapy via nanocarriers against infectious diseases. Eur. J. Pharm. Sci. 2019;127:121–141. doi: 10.1016/j.ejps.2018.10.017. - DOI - PubMed
    1. Zignol M., Dean A.S., Falzon D., van Gemert W., Wright A., van Deun A., Portaels F., Laszlo A., Espinal M.A., Pablos-Méndez A., et al. Twenty years of global surveillance of antituberculosis-drug resistance. N. Engl. J. Med. 2016;375:1081–1089. doi: 10.1056/NEJMsr1512438. - DOI - PubMed
    1. Gajdács M. The continuing threat of methicillin-resistant Staphylococcus aureus. Antibiotics. 2019;8:52. doi: 10.3390/antibiotics8020052. - DOI - PMC - PubMed

LinkOut - more resources